Supporting Info

12 downloads 155 Views 2MB Size Report
SSC-H. Live / Dead Stain. Dump-AF700. C. D. 8. -F. IT. C. FSC Single Cells. SSC Single ... TET APC+. TET ... mononuclear cells were selected by FSC and SSC.
Peptide 1

Peptide 2

Peptide 3 . . . .

. . . . Peptide 25 Assemble fluorochrome conjugated MHC multimers

Generate differentially encoded multimer combinations

Combine two color coded multimers for 25 epitopes and use for staining

QD655

QD705

Count QD800

CD8-FITC

CD8-FITC

TET QD800+

CD8+ / Dump- Cells

Dump-AF700

TET QD625+

QD625

QD605

APC TET QD705+

TET QD605+

Live / Dead Stain

CD8-FITC

CD8-FITC

CD8-FITC

CD8-FITC

PE

CD8-FITC

SSC-W TET APC+

TET PE+

TET QD655+

SSC-H

CD8-FITC

SSC-A

FSC-W FSC-H

FSC-A

Live Cells

SSC Single Cells

CD8-FITC

FSC Single Cells

Mononuclear Cells

TET PE-Cy7+

PE-Cy7

Supplementary Figure 1. Overview of combinatorial encoding approach. (A) MHC molecules charged with different peptides are each conjugated to a unique two-color fluorochrome code (exemplified by the red, green and blue fluorochromes). Sets of 25 pMHC multimers that each have a unique two-color code are combined for T cell staining. (B) Gating strategy applied for identification of pMHC-specific T cells by combinatorial coding. TILs were stained with a mixture of pMHC multimers plus the indicated antibodies. Single mononuclear cells were selected by FSC and SSC. Within the single cells, live cells were gated by a live/dead cell stain. Subsequently, anti-CD8-FITC positive and “dump-channel” (anti-CD4, -CD14, -CD19, -CD16-AF700) negative cells were selected (top right). (c) From the above gating, positive cells were selected in all eight fluorescent channels. Cells positive in two and only two different pMHC multimer channels are indicated in black, and cells negative in all channels are indicated in red. Cells positive in only one as well as cells positive in three or more pMHC multimer channels are gated out. The eight fluorochromes used are listed on the x-axis.

All antigens

10

20

D cumulative fraction of responses

0.05

0.10

0.15

0.20

0.25

0.30

measured responses random responses

5

10

15

20

25

number of patients

30

0.8 0

35

5

10

15

20

25

number of patients

30

35

30

35

OE antigens measured responses random responses

0.25

CT antigens

0

0.6

35

0.20

30

0.15

25

0.10

20

0.05

15

0.00

10

number of patients

0.00

cumulative fraction of responses

C

5

0.4

30

40



0.2



measured responses random responses

0.0

cumulative fraction of responses

50

60

experimental responses random responses

0

MDA antigens

B

0

cumulative number of responses

A

0

5

10

15

20

25

number of patients

Supplementary Figure 2. MD antigen- but not CT antigen-specific T cell responses are strongly focused towards specific epitopes. (A) The cumulative number of responses against epitopes in all antigen classes is shown as a function of the number of patients screened. The black line represents the mean +/- 95% confidence interval of 1000 randomized permutations (with replacement) of patient samples using the experimental data. The red line represents the predicted number of responses detected when 1000 randomized permutations are performed using randomly created patient-response tables (i.e., in which the probability of observing a T cell response is equal for each epitope, but in which the total number of responses is the same as in the experimental data). Note that there is a substantial saturation in the number of different responses observed in the experimental data. (B-D) The same analysis but now performed separately for the MD epitopes (B), CT epitopes (C), and OE epitopes (D), in each case expressed as a fraction of the total number of epitopes present within this antigen class. Note that the saturation observed in (a) can fully be attributed to recurrent recognition of MD epitopes.

B 1

MAGE C2LLF MAGE C2VIW MAGE A10GLY CDK4ACD CYP BVLE

0.1

0.01

0.001

1

2

3

4

5

TIL fragment culture

6

% CD8+ MHC-multimer+ cells of total CD8+ cells

% CD8+ MHC-multimer+ cells of total CD8+ cells

A

100

MART-1ELA MG50TLH

10 1 0.1 0.01

1

2

3

TIL fragment culture

Supplementary Figure 3. Random variability in TIL composition during in vitro culture. Contribution of indicated antigen-specific T cell populations (% of total CD8+ T cells) in parallel T cell cultures established from different tumor fragments of 2 patients (A, B). T cell cultures were initiated in separate wells, each containing one fragment, and cultured for approximately 2 weeks prior to analysis of T cell reactivity.

Protein

707-AP ATIC (AICRT) ATIC (AICRT) B-RAF B-RAF BA46 (MFGE8) BA46 (MFGE8) Bcl-2 Bcl-2 BCLX (L) BING-4 (WDR46) Cadherin 3/P-cadherin Cadherin 3/P-cadherin CDCA1/NUF2 CDCA1/NUF3 CDK4 CML28 (EXOSC5) COA-1 (UBXN11) COA-1 (UBXN11) CPSF1 CPSF1 cyclin B1 cyclin B1 cyclin D1 Cyclin I (CCNI) cyclophilin B (Cyp-B) cyclophilin B (Cyp-B) DAM-6, -10 (MAGE-B1, -B2) EphA2 EphA2 EphA2 EphA2 EZH2 EZH2 GnTV (MGAT5) GnTV (MGAT5) gp100 / Pmel17 gp100 / Pmel17 gp100 / Pmel17 gp100 / Pmel17 gp100 / Pmel17 gp100 / Pmel17 gp100 / Pmel17 gp100 / Pmel17 gp100 / Pmel17 gp100 / Pmel17 gp100 / Pmel17 HERV-K-MEL hsp70 hsp70 IDO LAGE-1 LAGE-1 Livin (ML-IAP) Livin (ML-IAP) Livin (ML-IAP)

Sequence

RVAALARDA RLDFNLIRV MVYDLYKTL LATEKSRWS LATEKSRWSG NLFETPVEA GLQHWVPEL WLSLKTLLSL PLFDFSWLSL YLNDHLEPWI CQWGRLWQL FIIENLKAA FILPVLGAV YMMPVNSEV KLATAQFKI ACDPHSGHFV ALVDAGVPM RLLASLQDL FMTRKLWDL KVHPVIWSL LMLQNALTTM AGYLMELCC AKYLMELTM LLGATCMFV LLDRFLATV KLKHYGPGWV VLEGMEVV FLWGPRAYA VLLLVLAGV TLADFDPRV IMNDMPIYM VLAGVGFFI FINDEIFVEL FMVEDETVL VLPDVFIRC VLPDVFIRCV LLDGTATLRL SLADTNSLAV IMDQVPFSV VLYRYGSFSV MLGTHTMEV ITDQVPFSV RLMKQDFSV RLPRIFCSC YLEPGPVTA AMLGTHTMEV KTWGQYWQV MLAVISCAV LLLLDVAPL LLDVAPLSL ALLEIASCL MLMAQEALAFL SLLMWITQC RLASFYDWLP SLGSPVLGL QLCPICRAPV

Protein

M2BP/LGALS3 MAGE-A1 MAGE-A10 MAGE-A2 MAGE-A2 MAGE-A2 MAGE-A2 MAGE-A3 MAGE-A3 MAGE-A3 MAGE-A4 MAGE-A6 MAGE-A8 MAGE-A8 MAGE-A9 MAGE-C2 MAGE-C2 MAGE-C2 (HCA587) MAGE-C2 (HCA587) MAGE-C2 (HCA587) MC1R Melan-A / MART-1 Melan-A / MART-1 Meloe-1 Meloe-2 Meloe-2 MG50 (PXDN) MG50 (PXDN) MG50 (PXDN) MG50 (PXDN) MG50 (PXDN) MG50 (PXDN) NY-ESO-1 / LAGE-2 NY-ESO-1 / LAGE-2 NY-ESO-1 / LAGE-2 P Polypeptide (OCA2) p53 p53 p53 p53 p53 p53 p53 p53 p53 p53 PGK1 PRAME PRAME PRAME PRAME PRDX5 PRDX5 (OMT3-12) RAB38 / NY-MEL-1 RAGE-1 RAGE-1

Sequence

RIDITLSSV KVLEYVIKV GLYDGMEHL LVQENYLEY KMVELVHFL YLQLVFGIEV LVHFLLLKY LVFGIELMEV FLWGPRALV KVAELVHFL GVYDGREHTV YLEYRQVPV GLMDVQIPT KVAELVRFL ALSVMGVYV ALKDVEERV LLFGLALIEV VIWEVLNAV KVLEFLAKL TLDEKVAELV TILLGIFFL ELAGIGILTV ILTVILGVL TLNDECWPA RLPPKPPLA RCPPKPPLA CMHLLLEAV TLHCDCEIL VLSVNVPDV WLPKILGEV RLGPTLMCL LLLEAVPAV SLLMWITQA QLSLLMWIT SLLMWITQCFL IMLCLIAAV KTCPVQLWV GLAPPQHLIRV RMPEAAPPV SLPPPGTRV LLPENNVLSPV YLGSYGFRL KLCPVQLWV SMPPPGTRV VVPCEPPEV LLGRNSFEV IIGGGMAFT SLYSFPEPEA VLDGLDVLL ALYVDSLFFL SLLQHLIGL LLLDDLLVSI AMAPIKVRL VLHWDPETV LKLSGVVRL PLPPARNGGL

Protein

Replication protein A SART-3 SART-3 secernin 1 SOX10 SOX10 SSX-2 SSX-2 STAT1-alpha/ß STEAP1 STEAP1 STEAP1 Survivin Survivin survivin survivin TAG-1 Telomerase Telomerase Telomerase Topoisomerase II TRAG-3 TRAG-3 TRAG-3 TRP-2 TRP-2 TRP-2 TRP-2 TRP-2 TRP2-6b tyrosinase tyrosinase tyrosinase XBP-1

Sequence

YLMDTSGKV LLQAEAPRL RLAEYQAYI KMDAEHPEL AWISKPPGV SAWISKPPGV RLQGISPKI KASEKIFYV KLQELNYNL FLYTLLREV LLLGTIHAL MIAVFLPIV RISTFKNWPFL LMLGEFLKL ELTLGEFLKL TLPPAWQPFL SLGWLFLLL RLVDDFLLV ILAKFLHWL RLFFYRKSV FLYDDNQRV ILLRDAGLV GLIQLVEGV VLGEAWRDQV FVWLHYYSV VYDFFVWLHY SLDDYNHLV TLDSQVMSL SVYDFFVWL ATTNILEHY CLLWSFQTSA MLLAVLYCL YMDGTMSQV LLSGQPASA

Supplementary Table 1. Set of HLA-A2-restricted melanoma-associated epitopes used for T cell profiling. Epitopes to which reactivity was detected in at least one patient are highlighted in grey.